All In Biotech

Free tool

FAERS Monitor: Retin-A-Micro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020475 or its brand name (Retin-A-Micro, Tretinoin). Reports on generic versions are filed under their own applications.

Reports

6,689

Serious

4,179

62% of reports

Hospitalization

1,453

Death reported

854

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use889
  • drug ineffective746
  • pain498
  • product use in unapproved indication485
  • vomiting452
  • paraesthesia374
  • abdominal pain upper368
  • rash366
  • nausea354
  • diarrhoea352
  • headache339
  • maternal exposure during pregnancy339
  • taste disorder332
  • gastrooesophageal reflux disease330
  • hypoaesthesia328

Reports by year received

View as table
YearReports
200439
200533
200624
200740
2008118
200975
201082
2011102
2012165
2013107
2014149
2015236
2016357
2017371
2018466
2019364
2020384
2021428
2022513
2023573
2024681
2025815
2026567

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
taste disorderSignal33252.347.016,397
gastrooesophageal reflux diseaseSignal33012.911.63,622
maternal exposure during pregnancySignal33912.010.83,409
paraesthesiaSignal3747.56.82,108
hypoaesthesiaSignal3286.96.21,658
product use in unapproved indicationSignal4856.25.72,114
abdominal pain upperSignal3685.65.11,407
off label useSignal8893.23.01,395
vomitingSignal4523.02.8624
rashSignal3662.62.4379
painSignal4982.62.3482
drug ineffective7461.81.7271
diarrhoea3521.71.5107
headache3391.71.5100
nausea3541.41.343

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.